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1. SUSTAINED RELEASE DRUG DELIVERY SYSTEM 
 Sustained release dosage form is designed to maintain constant levels of a 
drug in the patient’s bloodstream by releasing the drug over an extended period. 
Maintaining constant blood levels of the drug in the bloodstream increases the 
therapeutic effectiveness of the drug. Drugs are defined precisely under some 
acts1 . It is the single active chemical entity present in a medicine that is used for 
diagnosis, prevention, treatment, cure of a disease2. Yet to a common man they 
are just substances which are administered to win back an individual from the 
states of disease or ill health to the normal health. The drugs also had mysterious 
origins and hence the word drug was a form of the word called ‘drogues’ meaning 
of mysterious origin. The word disease can be expressed as a combination of ‘dis’ 
and ‘ease’ indicating absence of easiness or well being or a feeling contrary to the 
feeling of health. 
 With many drugs the basic goal of therapy is to achieve a steady state 
blood or tissue level that is therapeutically effective and nontoxic for an extended 
period of time. The basic objective in dosage form design is to optimize the 
delivery of medication so as to achieve a measure of control of therapeutic effect 
in the face of uncertain fluctuations in the in-vivo environment in which drug 
release takes place. The appropriate dosage form and correct dose will ensure the 
maximum availability of the drug. The pharmaceutical industry provides a variety 
of dosage forms and dosage levels of particular drugs thus enabling the physician 
to control the onset and duration of drug therapy by altering the dose or mode of 
administration3. 
Scope of Sustained Drug Delivery 
Sustained release delivery systems are designed to achieve a prolonged 
therapeutic effect by continuously releasing medication over an extended period 
of time after administration of a single dose. A sustained release dosage forms 
leads to better management of the acute or chronic disease condition. The basic 
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rationale of a sustained drug delivery system is to optimize the biopharmaceutic, 
pharmacokinetic and pharmacodynamic properties of a drug in such a way that its 
utility is maximized through reduction in side effects and cure or control of 
condition in the shortest possible time by using smallest quantity do drug, 
administered by the most suitable route. This is usually accomplished by 
maximizing drug availability, i.e., by attempting to attain maximum rate and 
extent of drug absorption; however, control of drug action through formulation 
also implies controlling bioavailability to reduce drug absorption rates. Sustained 
release tablets and capsules are commonly taken only once or twice daily, 
compared with counterpart conventional forms that may have to take three or four 
times daily to achieve the same therapeutic effect.  
Typically, sustained release products provide an immediate release of drug 
that promptly produces the desired therapeutic effect, followed by gradual release 
of additional amounts of drug to maintain this effect over a predetermined period. 
The sustained plasma drug levels provided by sustained release products 
eliminates the need for night dosing, which benefits not only the patients but the 
care given as well. 
 The novel system of drug delivery offer a means of improving the 
therapeutic effectiveness of incorporated drugs by providing sustained, controlled 
delivery and/or targeting the drug to desired site4. Oral route has been the most 
popular and successfully used for sustained delivery of drugs because of 
convenience and ease of administration, greater flexibility in dosage form design 
and ease of production and low cost of such a system. The sustained release 
systems for oral use are mostly solid and based on dissolution, diffusion or a 
combination of both mechanisms in the control of release of drugs.  
Sustained release can be achieved by, 
• Incorporating the drug in a carrier system 
• Altering the structure of the drug at the molecular level 
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• Controlling the input of the drug into the bio-environment to ensure a 
programmed and desirable bio-distribution. 
 The primary objectives are to ensure safety and to improve efficacy of    
drugs as well as patient compliance. This is achieved by better control of plasma   
drug levels and less frequent dosing. 
Advantages of Sustained Release Dosage Form4 
i. Frequency of drug administration is reduced. 
ii. Patient compliance can be improved, and drug administration can be made 
more convenient. 
iii. The blood level oscillation characteristic of multiple dosing of 
conventional dosage forms is reduced, because a more even blood level is 
maintained. 
iv. Implicit in the design of sustained release forms, is that the amount of drug 
administered can be reduced, thus maximizing availability with a 
minimum dose. 
v. The safety margin of high-potency drugs can be increased, and the 
incidence of both local and systemic adverse side effects can be reduced in 
sensitive patients. 
 
Disadvantages 
i. Administration of sustained release medication does not permit the prompt 
termination of therapy. 
ii. The physician has less flexibility in adjusting dosage regimens. This is 
fixed by the dosage form regimen. 
iii. Sustained release forms are designed for the normal basis of average drug 
biologic half-lives. Consequently, disease states that alter drug disposition, 
significant patient variation, so forth are not accommodated. 
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iv. Economically more costly processes and equipment are involved in 
manufacturing many sustained release forms. 
The parameters that must be taken into account in optimizing sustained release 
dosage form designs are5,  
Ke    Elimination rate constant 
 Ka  Absorption rate constant 
 Vd  Apparent distribution volume 
 Di  Loading or immediately available portion of the dose 
 Dm  Maintenance or slowly available portion of the dose 
 Tm  Time at which release of maintenance dose begins 
 Kr  The specific rate of release of the maintenance dose 
 
Factors to Be Considered for the Formulation of Sustained Release6, 7 
Physicochemical properties 
  a) Dose size: 
For a ideal sustained release formulation the dose size should be not more 
than 500mg. 
  b) Aqueous solubility: 
 The drug should not be more water soluble or poorly soluble; moderate 
solubility is needed. 
c) Partition co-efficient: 
 Both lipophillic or hydrophilic drugs are difficult to process and should 
possess optimum partition co-efficient. 
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d) Molecule size: 
 Large molecules show small diffusion co-efficient and may be difficult to 
place into a suitable sustained release system. Drugs of molecular weight 500-700 
finds no difficult in processing. 
e) Drug stability: 
It should be significantly stable over an extended period of time in the 
GIT. Generally non-potent drugs are more stable when formulated as sustained 
release form. It should not show high degree of plasma protein binding. 
Route of administration 
Some routes of administration exert a negative influence on drug efficacy 
especially during chronic administration. Many physiological constrains improved 
by the particular route i.e., GI mobility, blood supply, first pass metabolism. 
 
Biological properties 
a) Absorption: 
 Drugs that are slowly absorbed or adsorbed with variable absorption rate 
are poor candidates for sustained release. It is assumed that the GI transit time of 
10-12 hrs, to be ideal for sustained release. 
b) Metabolism: 
 Rapid metabolism leads to poor formulation in extended release. 
c) Distribution: 
 Drugs with high apparent volumes of distribution which in turn influences 
the rate of elimination for the drug are poor candidates for sustained release. 
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d) Duration of action 
 Drugs with short half life and high doses impose a constraint because of 
the dose size needed and those with a long half life are inherently sustained. 
e) Therapeutic index 
 Drugs with narrow therapeutic range require precise control over the blood 
level of drug placing a constraint on sustained release. 
f) Length of drug therapy 
 Expected length of drug therapy to achieve control or curve of ailment is 
an important factor, in design of control release products. 
g) Disease state 
 Pathophysiological state of subject plays an important part in the design of 
suitable controlled release delivery system. 
Formulation Methods of Achieving Sustained Drug Release8 
 All sustained release formulations employ a chemical or physical barrier to 
provide slow release of the maintenance dose. Many formulation techniques have 
been used to ‘build’ the barrier into the peroral dosage form. These techniques 
include the use of coatings, embedding drugs in a wax, fat or plastic matrix, 
microencapsulation, chemical binding to ion-exchange resins and incorporation in 
an osmotic pump. The initial rapidly releasing priming dose of drug may be 
provided by incorporating that portion of the drug in a separate rapidly releasing 
form in the dosage form, for instance, as uncoated, rapidly releasing granules or 
pellets along with coated, slowly releasing granules or pellets in a tablet or hard 
gelatin capsule dosage form. 
 Alternatively, immediate and rapid release of the priming dose has been 
achieved by virtue of the position of that portion of the drug being at the surface 
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of a porous wax or plastic matrix. The maintenance dose is provided by drug 
embedded deeper in the porous matrix.  
 
Fig–1. Repeat Action versus Sustained Action Drug Therapy 
 
 
 
 
                                     
 
 
A repeat action tablet may be distinguished from its sustained release 
counterpart by the fact that the repeat action product does not release the drug 
contained therein in a slow controlled manner and consequently doesn’t give a 
plasma concentration-time curve which resembles that of sustained release 
product9. A repeat action tablet usually contains two doses of drug, the first dose 
being released immediately following peroral administration in order to provide a 
rapid onset of the therapeutic response. The release of the second dose is delayed, 
usually by means of an enteric coat. Consequently when the enteric coat 
surrounding the second dose is breached by the intestinal fluids, the second dose is 
released immediately. 
Classification10 
From a mathematical-modeling point of view, sustained-release systems 
may be classified according to the controlling physical mechanism(s) of release of 
the incorporated drug. We have proposed a convenient method based on the 
mechanism of transport for categorizing them as diffusion-controlled, swelling-
controlled, osmotically controlled, and chemically controlled systems. Sustained 
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release of drugs, proteins, and other bioactive agents can be achieved by 
incorporating them either in dissolved or dispersed form in polymers. 
 
Diffusion-Controlled drug delivery system 
Diffusion is the most common mechanism for controlling the release. 
There are two major types of diffusion-controlled systems; reservoir devices and 
membrane devices. Drug release from each type of system occurs by diffusion 
through the macromolecular mesh or through the water-filled pores. 
 
a) Reservoir systems 
 Reservoir systems consist of a polymeric membrane surrounding a core 
containing the drug. The rate-limiting step for drug release is diffusions through 
the outer membrane of the device. To maintain a constant release rate or flux of 
drug from the reservoir, the concentration difference must remain constant. This 
can be achieved by designing a device with excess solid drug in the core. Under 
these conditions, the internal solution in the core remains saturated. This type of 
device is an extremely useful device as it allows for time - independent of zero-
order release. The major drawback of this type of drug delivery system is the 
potential for catastrophic failure of the device. 
 
b) Matrix system 
 In matrix devices, the drug is dispersed throughout the three-dimensional 
structure of the polymer. Release occurs due to diffusion of the drug throughout 
the macromolecular mesh or water-filled pores. In these systems, the release rate 
is proportional to time to the one-half power. This is significant in that it is 
impossible to obtain time independent of zero-order release in this type of system 
with simple geometries. 
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 Drug can be incorporated into the gels by equilibrium partitioning, where 
the gel is swollen to equilibrium in concentrated drug solution, or during the 
polymerization reaction. Equilibrium partitioning is the favorable loading method 
for drug-polymer systems that could be degraded during the polymerization. 
 C) Swelling –Controlled release systems 
  
         In swelling-controlled release systems, the drug is dispersed within a glassy 
polymer. Upon contact with biological fluid, the polymer begins to swell. No drug 
diffusion occurs through the polymer phase. As the penetrant enters the glassy 
polymer, the glass transition temperature of the polymer is lowered allowing for 
relaxations of the macromolecular chains. The drug is able to diffuse out of the 
swollen, rubbery area of the polymers. This type of system is characterized by two 
moving fronts: the front separating the swollen (rubbery) portion and the glassy 
regions which moves with velocity, υ, and the polymer-fluid interface. The rate of 
drug release is controlled by the velocity and position of the front dividing the 
glassy and rubbery portions of the polymer. 
 
 For true swelling-controlled release systems, the diffusion exponent, n, is 
1. This type of transport is known as Case II transport and results in zero-order 
release kinetics. However, in some cases, drug release occurs due to a 
combination of macromolecular relaxations and Fickian diffusion. In this case, the 
diffusion exponent is between 0.5 and 1. This   type of transport is known as 
anomalous or non-Fickian transport. 
 
d) Chemically-Controlled release systems 
 
 There are two major types of chemically controlled release systems: 
erodible drug delivery systems, and pendent chain systems in erodible systems, 
drug release occurs due to degradation or dissolution of the polymer. In pendent 
chain systems, the drug is affixed to the polymer backbone through degradable 
linkages. As these linkages degrade, the drug is released. 
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e) Erodible drug delivery systems 
 Erodible drug delivery systems, also known as degradable or absorbable 
release systems, can be either matrix or reservoir delivery systems. In reservoir 
devices, an erodible membrane surrounds the drug core. If the membrane erodes 
significantly after the drug release is complete, the dominant mechanism for 
release would be diffusion. Predictable, zero-order release could be obtained with 
these systems. In some cases, the erosion of the membrane occurs simultaneously 
with the drug release. As the membrane thickness decreased due to erosion, the 
drug delivery rate would also change. Finally in some erodible reservoir devices, 
the drug diffusion in the outer membrane does not occur. Under these conditions, 
drug release does not occur until the outer membrane erodes completely. In this 
type of device, the entire contents are released in a single, rapid burst. 
 
 For erodible matrix devices, the drug is dispersed within the three-
dimensional structure of the polymer. Drug release is controlled by drug diffusion 
through the gel of erosion of the polymer. In true erosion-controlled devices, the 
rate of drug diffusion is significantly slower than the rate of polymer erosion, and 
the drug is released as the polymer erodes. In erodible system, there are three 
major mechanisms for erosion of the polymer.       
           
Degradation of the cross-links 
This degradation can occur by hydrolysis of water-labile linkages, 
enzymatic degradation of the junctions, or dissolution of physical cross-links such 
as entanglements or crystallites in semi - crystalline polymers.  
Solubilization of insoluble or hydrophobic polymers 
           This could occur as a result of hydrolysis, ionization, or protonation of 
pendent groups along the polymer chains. Degradation of backbone bonds to 
produce small molecular weight molecules. Typically, the degradation products 
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are water soluble. This type of erosion can occur by hydrolysis of water-labile 
backbone linkages or by enzymatic degradation of backbone linkages. 
Environmentally responsive systems 
 Environmentally responsive materials show drastic changes in their 
swelling ratio due to changes in their external pH, temperature, ionic strength, 
nature and composition of the swelling agent, enzymatic or chemical reaction, and 
Electrical or magnetic stimulus In most responsive networks, a critical point exists 
at which this transition occurs. 
  
Responsive materials are unique in that there are many different 
mechanisms for drug release and many different types of release systems based on 
these materials. For instance, in the most cases drug release occurs when the gel is 
highly swollen and is typically controlled by gel swelling, drug diffusion, or a 
coupling of swelling and diffusion. However, in a few instances, drug release 
occurs during gel syneresis by a squeezing mechanism. Also, drug release can 
occur due to erosion of the polymer caused by environmentally responsive 
swelling. Another interesting characteristic about many responsive gels is that the 
mechanism causing the network structural changes can be entirely reversible in 
nature. 
 
 The ability of these materials to exhibit rapid changes in their swelling 
behavior and pore structure in response to changes in environmental conditions 
lends these materials favorable characteristics as carriers for bioactive agents, 
including peptides and proteins. This type of behavior may allow these materials 
to serve as self regulated, pulsatile drug delivery system. 
 
 Initially, the gel is in an environment in which no swelling occurs. As a 
result, very little drug release occurs. However, when the environment changes 
and the gel swells rapid drug release occurs (either by Fickian diffusion, 
anomalous transport, or Case II transport). When the gel collapses as the 
environment changes, the release can be turned off again. This can be repeated 
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over numerous cycles. Such systems could be of extreme importance in the 
treatment of chronic diseases such as diabetes. 
 
POLYMER FOR DRUG DELIVERY 
 
 The choice of appropriate polymer, particle size and manufacturing 
process will primarily depend on the bio-acceptability of the polymer. 
Characteristics of Ideal Polymer System 
 An ideal polymer system should possess the following char 
 i) Inert and compatible with the environment  
 ii) Non-Toxic 
 iii) Easily administered 
  iv) Inexpensive to fabricate 
 v) Good mechanical strength. 
 
Inert polymer matrices are most commonly employed for evaluation of 
sustained action dosage forms. Three classes of retardant materials demonstrating 
different approaches have been used for matrix formulations. 
• Drugs consist of retardant material that forms insoluble or skeleton 
matrices. 
• Drugs consist of water insoluble materials that are potentially erodable. 
• Drugs consist of polymers that form hydrophilic matrices. 
 
Classification of Polymers11 
         Polymers based on back bone 
      a) Polymers with carbon chain backbone: 
¾ Polyethylene 
¾ Polypropylene 
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¾ Poly vinyl chloride 
¾ Poly vinyl alcohol 
¾ Poly acrylamide 
¾ Poly vinyl pyrrolidone 
 
        b) Polymers with heterochain backbone: 
¾ Poly ethylene oxide 
¾ Cellulose (poly glycoside, β-1,4) 
¾ Amylase (polyglucose α-1,4) 
¾ Polydimethyl silaxone 
¾ Pectinic acid (polygalactouronoside) 
 
Polymer classification based on source  
a) Natural polymers 
      Protein based  :  albumin, collagen, gelatin, etc. 
Polysaccharides        :  agarose, alginate, chitosan, cyclodextrin,  
hyaluronic acid, etc. 
  b) Synthetic polymers 
    Bio-degradable 
Poly esters  :  poly lactic acid, polyglycolic acid,  
poly diaxanones, polyhydroxy butyrate, etc. 
Polyanhydrides  :   polysabacic acid, polyadipic acid,    
     polyterephthalic acid, etc. 
Polyamides  :  polyimino carbonates, polyamino acids 
     Phosphorous based: polyphosphates,  
polyphosphonates, polyphosphazenes, etc. 
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     Others   : Polyurethanes, polyorthoesters,  
polydihydropyrans, polyacetals, etc. 
b) Non bio-degradable 
Cellulose derivatives  : Carboxymethyl cellulose, ethyl                        
cellulose, HPMC, cellulose acetate, etc. 
Silicones   : Polydimethyl siloxane, colloidal silicate 
Acrylic  polymers  :         Polymethacrylates, polymethylmethacrylate, 
     polyhydroethyl methacrylate, etc. 
d) Others   : Polyvinyl pyrrolidone, ethyl vinyl   acetate,  
     Poloxamers, poloxamines, etc. 
Based on nature of physical characteristics 
Insoluble inert polymers :  Dibasic calcium phosphate, polyamides,  
  Polyvinyl   chloride, etc. 
e) Insoluble erodable  :   Methyl cellulose, stearylalcohol, castor wax,  
 ( lipid excipients)  PEG monostearate, carnauba wax, etc. 
MethacrylateÆEthacrylate : Copolymers 
 
Hydrophilic polymers :  Methyl cellulose (400 CPS, 4000 CPS),  
  Hydroxyl ethyl cellulose,  guargum,  HPMC 
(60 HG, 90 HG) (25 CPS, 4000 CPS,  
                                                          15000 CPS), sodium carboxy methyl  
cellulose, etc  
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Hydrophilic polymer matrix system 
 
 Hydrophilic polymer matrix systems (HPMS) are widely used in oral 
controlled drug delivery because they make it easier to a desirable drug-release 
profile, as they are cost effective and have abroad US FDA acceptance. It consists 
of hydrophilic polymer, drug and other excipients distributed throughout the 
matrix.  This dynamic system is dependent on polymer wetting, hydration and 
dissolution for controlled release of drug.  At the same time, other soluble 
excipients (or) drug substance will also wet, dissolve and diffuse out of the matrix, 
whereas insoluble excipients (or) drug substances will be  held in place until the 
surrounding polymer, excipients (or) drug complex erodes (or) dissolves away. 
           Matrix controlled release tablet are relatively simple system that are more 
forgiving of variations in ingredients, production methods and end-use conditions 
when compared to coated controlled release tablets of other systems.  This results 
in more uniform release profiles with a high resistance to drug dumping. 
Hydrophilic matrix systems are relatively easy to formulate with existing 
conventional equipments and processing method. One goal of this study was to 
develop uncoated HPMC matrix tablet by wet granulation process, evaluating the 
relationship and influence of excipeints11. 
Advantages of hydrophilic matrix system 
¾ Generally regarded as a safe excipients 
¾ Simple concept 
¾ Erodable – reducing ghost matrices 
¾ Easy to manufacture by 
 Direct compression 
 Wet granulation 
 Roller compaction 
¾ Possible to obtain different release 
 
  
INTRODUCTION  
 
   16 
 
Disadvantages 
¾ Need optimal rate controlling polymers 
¾ Scale of problems 
MICROENCAPSULTION12 
Microencapsulation is a process whereby small discrete solid particles or 
small liquid droplets are surrounded and enclosed by an intact shell. 
Microencapsulation is used to modify and delayed drug release form 
pharmaceutical dosage forms. A well designed controlled drug delivery system 
can overcome some of the problems of conventional therapy and enhance the 
therapeutic efficacy of a particular drug.  
It is the reliable means to deliver the drug to the target site with specificity, 
if modified, and to maintain the desired concentration at the site of interest 
without untoward effects.  
Microspheres received much attention not only for prolonged release, but 
also for targeting of anticancer drugs to the tumor. The intent of the paper is to 
highlight the potential of microencapsulation technique as a vital technique in 
novel drug delivery. 
The Reasons for Microencapsulation 
The reasons for microencapsulation are in some countless cases, the core 
must be isolated from its surroundings, as in vitamins from the deterioration a 
volatile core, improving the handling of a sticky material, or isolatin core from 
chemical a attack. The problem may be as simple as masking the taste or odor of 
the core, or as complex as increasing the selectivity of an adsorption or extraction 
process. 
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Fundamental Considerations 
The realization of the potential that microencapsulation offers involves a 
basic understanding of the general properties of microcapsules, such as the nature 
of the core and coating materials, the stability and release characteristics of the 
coated materials and the microencapsulation methods. 
Core Material 
The core material, defined as the specific material to be coated, can be 
liquid or solid in nature. The composition of the core material can be varied as the 
liquid core can include dispersed and/or dissolved material. The solid core can be 
mixture of active constituents, stabilizers, diluents, excipients and release-rate 
retardants or accelerators. The ability to vary the core materials composition 
provides definite flexibility and utilization of this characteristic often allows 
effectual design and development of the desired microcapsules properties. 
Coating Material 
The selection of appropriate coating material decides the physical and 
chemical properties of the resultant microcapsules/microspheres.  
Fig 2 - Encapsulation 
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While selecting a polymer the product requirements i.e. stabilization, 
reduced volatility, release characteristics, environmental conditions, etc. should be 
taken into consideration. The polymer should be capable of forming a film that is 
cohesive with the core material. It should be chemically compatible, non-reactive 
with the core material and provide the desired coating properties such as strength, 
flexibility, impermeability, optical properties and stability. Generally hydrophilic 
polymers, hydrophobic polymers (or) a combination both are used for the 
microencapsulation process. A number of coating materials gelatin have been 
used successfully; examples of these include polyvinyl alcohol, ethyl cellulose, 
cellulose acetate phthalate and styrene maleic anhydride. The film thickness can 
be varied considerably depending on the surface area of the material to be coated 
and other physical characteristics of the system. The microcapsules may consist of 
a single particle or clusters of particles.After isolation from the liquid 
manufacturing vehicle and drying, the material appears as a free flowing powder. 
The powder is suitable for formulation as compressed tablets, hard gelatin 
capsules, suspensions, and other dosage forms  
Multiparticulate Drug Delivery Systems14  
 
Multiparticulate drug delivery system applies specially to multiple 
particles such as pellets, beads, microspheres, microcapsules. In recent years, 
multiparticulate dosage forms or microparticles have gained in popularity for a 
variety of reasons. Considerable research efforts have been spent on oral sustained 
or controlled release multiparticulate drug delivery system due to its advantages 
over monolithic dosage forms.  
 
Multi-particulate drug delivery systems are mainly oral dosage forms 
consisting of a multiplicity of small discrete units, each excihibit some desired 
characteristics. In these systems, the dosage of the drug substances is divided on a 
plurality of subunit, typically consisting of thousands of spherical particles with 
diameter of 0.05-2.00mm.  
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Thus multiparticulate dosage forms are pharmaceutical formulations in 
which the active substance is present as a number of small independent subunits. 
To deliver the recommended total dose, these subunits are filled into a sachet and 
encapsulated or compressed into a table 
 
 
 
  
 
Fig – 3   MICROSPHERES CHART 
The system is based on the expansion of the core (non effervescent FDDS 
or low density approach), which lead to floating due to low density. Also the air 
entrapped by the swollen polymer confers buoyancy to this dosage forms. Floating 
multiparticulate oral sustained release drug delivery system includes; hollow 
microspheres (microballoons), low density floating micropellets and Floating 
microbeads. Multiparticulate carriers (microspheres) are defined as homogeneous, 
monolithic particles in the size range of about 0.1-1000 µm and are widely used as 
drug carriers for controlled release. Multiparticulate carrier systems made from 
the naturally occurring biodegradable polymers have attracted considerable 
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attention for several years in sustained drug delivery. Recently dosage forms that 
can precisely control the release rates and target drugs to a specific body site have 
created enormous impact in formulation and development of novel drug delivery 
systems. 
 
Microspheres form an important part of such novel drug delivery systems. 
They have varied applications and are prepared using various polymers. However, 
the success of these microspheres is limited due to their short residence time at the 
site of absorption. It would, therefore be advantageous to have means for 
providing an intimate contact of the drug delivery system with the absorbing 
membranes. This can be achieved by coupling gastroretentive and bioadhesion 
characteristics to multiparticulates and developing gastroretentive bioadhesive, 
multiparticulates. These multiparticulates have advantages like efficient 
absorption and enhanced bioavailability of the drugs due to a high surface to 
volume ratio, a much more intimate contact with the mucus layer and specific 
targeting of drugs to the absorption site4. It is stated that, ‘the multiparticulates’ 
float on the stomach contents, and then adhere to the mucous linings as the 
stomach empties (Figure 2). The release of drug from the system can be controlled 
to coincide with the half-life emptying of the system from the stomach.  
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Fig – 4 Proposed mechanism for retention of microspheres in the human 
stomach 
 
The floating multiparticulate oral sustained release drug delivery system 
have advantages like efficient absorption and enhanced bioavailability of the 
drugs due to a high surface to volume ratio, a much more intimate contact with the 
mucus layer and specific targeting of drugs to the absorption site. 
 
Floating multiparticulates drug delivery system has following objects; 
 
•  Sustain release or prolong release medication 
•  Taste masking 
•  Improve stability 
•  Increase solubility or dispersability 
•  Increase therapeutic effciency.  
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HYPERTENSION15 
Hypertension (HTN) or high blood pressure is a chronic medical condition in 
which the systemic arterial blood pressure is elevated. It is the opposite of 
hypotension. It is classified as either primary (essential) or secondary. About 90–
95% of cases are termed "primary hypertension", which refers to high blood 
pressure for which no medical cause can be found. The remaining 5–10% of cases 
(Secondary hypertension) are caused by other conditions that affect the kidneys, 
arteries, heart, or endocrine system 
Persistent hypertension is one of the risk factors for stroke, myocardial 
infarction, heart failure and arterial aneurysm, and is a leading cause of chronic 
kidney failure. Moderate elevation of arterial blood pressure leads to shortened 
life expectancy. Dietary and lifestyle changes can improve blood pressure control 
and decrease the risk of associated health complications, although drug treatment 
may prove necessary in patients for whom lifestyle changes prove ineffective or 
insufficient. 
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Classification16                  
       The variation in pressure in the left ventricle and the aorta  over two cardiac 
cycles ("heart beats"), showing the definitions of systolic and diastolic pressure 
Table-1.Classification of BP 
 
Classification 
Systolic pressure Diastolic pressure 
mmHg kPa mmHg kPa 
Normal 90–119 12–15.9 60–79 8.0–10.5 
Prehypertension 120–139 16.0–18.5 80–89 10.7–11.9 
Stage 1 140–159 18.7–21.2 90–99 12.0–13.2 
Stage 2 ≥160 ≥21.3 ≥100 ≥13.3 
Isolated systolic 
hypertension 
≥140 ≥18.7 <90 <12.0 
 
Blood pressure is usually classified based on the systolic and diastolic 
blood pressures. Systolic blood pressure is the blood pressure in vessels during a 
heart beat. Diastolic blood pressure is the pressure between heartbeats. A systolic 
or the diastolic blood pressure measurement higher than the accepted normal 
values for the age of the individual is classified as prehypertension or 
hypertension. 
Hypertension has several sub-classifications including, hypertension stage 
I, hypertension stage II, and isolated systolic hypertension. Isolated systolic 
hypertension refers to elevated systolic pressure with normal diastolic pressure 
and is common in the elderly. 
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SIGN AND SYMPTOMS17 
Accelerated hypertension 
Accelerated hypertension is associated with headache, drowsiness, 
confusion, vision disorders, nausea, and vomiting symptoms which are 
collectively referred to as hypertensive encephalopathy. Hypertensive 
encephalopathy is caused by severe small blood vessel congestion and brain 
swelling, which is reversible if blood pressure is lowered. 
Children 
Some signs and symptoms are especially important in newborns and 
infants such as failure to thrive, seizures, irritability, lack of energy, and difficulty 
breathing. In children, hypertension can cause headache, fatigue, blurred vision, 
nosebleeds, and facial paralysis.  
Even with the above clinical symptoms, the true incidence of pediatric 
hypertension is not known. In adults, hypertension has been defined due to the 
adverse effects caused by hypertension. However, in children, similar studies have 
not been performed thoroughly to link any adverse effects with the increase in 
blood pressure. Therefore, the prevalence of pediatric hypertension remains 
unknown due to the lack of scientific knowledge. 
Secondary hypertension 
Some additional signs and symptoms suggest that the hypertension is 
caused by disorders in hormone regulation. Hypertension combined with obesity 
distributed on the trunk of the body, accumulated fat on the back of the neck 
('buffalo hump'), wide purple marks on the abdomen (abdominal striae), or the 
recent onset of diabetes suggests that an individual has a hormone disorder known 
as Cushing's syndrome. Hypertension caused by other hormone disorders such as 
hyperthyroidism, hypothyroidism, or growth hormone excess will be accompanied 
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by additional symptoms specific to these disorders. For example, hyperthyrodism 
can cause weight loss, tremors, heart rate abnormalities, reddening of the palms, 
and increased sweating. Signs and symptoms associated with growth hormone 
excess include coarsening of facial features, protrusion of the lower jaw, 
enlargement of the tongue, excessive hair growth, darkening of the skin color, and 
excessive sweating.. Other hormone disorders like hyperaldosteronism may cause 
less specific symptoms such as numbness, excessive urination, excessive 
sweating, electrolyte imbalances and dehydration, and elevated blood alkalinity. 
and also cause of mental pressure. 
 
Pregnancy 
Hypertension in pregnant women is one symptom of pre-eclampsia. Pre-
eclampsia can progress to a life-threatening condition called eclampsia, which is 
the development of protein in the urine, generalized swelling, and severe seizures. 
Other symptoms indicating that brain function is becoming impaired may precede 
these seizures such as nausea, vomiting, headaches, and vision loss. 
 
In addition, the systemic vascular resistance and blood pressure decrease 
during pregnancy. The body must compensate by increasing cardiac output and 
blood volume to provide sufficient circulation in the utero-placental arterial bed.  
 
Causes 
Essential hypertension 
 
Essential hypertension is the most prevalent hypertension type, affecting 
90–95% of hypertensive patients. Although no direct cause has been identified, 
there are many factors such as sedentary lifestyle, smoking, stress, visceral 
obesity, potassium deficiency (hypokalemia), obesity (more than 85% of cases 
occur in those with a body mass index greater than 25), salt (sodium) 
sensitivity,alcohol intake, and vitamin D deficiency that increase the risk of 
developing hypertension. Risk also increases with aging, some inherited genetic 
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mutations, and having a family history of hypertension. An elevated level of renin, 
a hormone secreted by the kidney, is another risk factor, as is sympathetic nervous 
system overactivity. Insulin resistance, which is a component of syndrome X (or 
the metabolic syndrome), is also thought to contribute to hypertension. Recent 
studies have implicated low birth weight as a risk factor for adult essential 
hypertension.  
 
Secondary hypertension 
Secondary hypertension by definition results from an identifiable cause. 
This type is important to recognize since it's treated differently to essential 
hypertension, by treating the underlying cause of the elevated blood pressure. 
Hypertension results in the compromise or imbalance of the pathophysiological 
mechanisms, such as the hormone-regulating endocrine system, that regulate 
blood plasma volume and heart function. Many conditions cause hypertension, 
some are common and well recognized secondary causes such as Cushing's 
syndrome which is a condition where the adrenal glands overproduce the hormone 
cortisol. In addition, hypertension is caused by other conditions that cause 
hormone changes such as hyperthyroidism, hypothyroidism (citation needed), and 
certain tumors of the adrenal medulla (e.g., pheochromocytoma). Other common 
causes of secondary hypertension include kidney disease, obesity/metabolic 
disorder, pre-eclampsia during pregnancy, the congenital defect known as 
coarctation of the aorta, and certain prescription and illegal drugs. 
 Pathophysiology 
Most of the mechanisms associated with secondary hypertension are 
generally fully understood. However, those associated with essential (primary) 
hypertension are far less understood. What is known is that cardiac output is 
raised early in the disease course, with total peripheral resistance (TPR) normal; 
over time cardiac   Output drops to normal levels but TPR is increased. Three 
theories have been proposed to explain this: 
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• Inability of the kidneys to excrete sodium, resulting in natriuretic factors 
such as Atrial Natriuretic Factor being secreted to promote salt excretion 
with the side effect of raising total peripheral resistance. 
• An overactive Renin-angiotensin system leads to vasoconstriction and 
retention of sodium and water. The increase in blood volume leads to 
hypertension.  
• An overactive sympathetic nervous system, leading to increased stress 
responses.  
It is also known that hypertension is highly heritable and polygenic 
(caused by more than one gene) and a few candidate genes have been postulated 
in the etiology of this condition.  
Recently, work related to the association between essential hypertension 
and sustained endothelial damage has gained popularity among hypertension 
scientists. It remains unclear however whether endothelial changes precede the 
development of hypertension or whether such changes are mainly due to long 
standing elevated blood pressures. 
Diagnosis 
Hypertension is generally diagnosed on the basis of a persistently high 
blood pressure. Usually this requires three separate sphygmomanometer (see 
figure) measurements at least one week apart. Often, this entails three separate 
visits to the physician's office. Initial assessment of the hypertensive patient 
should include a complete history and physical examination. Exceptionally, if the 
elevation is extreme, or if symptoms of organ damage are present then the 
diagnosis may be given and treatment started immediately. 
Once the diagnosis of hypertension has been made, physicians will attempt 
to identify the underlying cause based on risk factors and other symptoms, if 
present. Secondary hypertension is more common in preadolescent children, with 
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most cases caused by renal disease. Primary or essential hypertension is more 
common in adolescents and has multiple risk factors, including obesity and a 
family history of hypertension. Laboratory tests can also be performed to identify 
possible causes of secondary hypertension, and determine if hypertension has 
caused damage to the heart, eyes, and kidneys. Additional tests for Diabetes and 
high cholesterol levels are also usually performed because they are additional risk 
factors for the development of heart disease require treatment.  
Creatinine (renal function) testing is done to determine if kidney disease is 
present, which can be either the cause or result of hypertension. In addition, it 
provides a baseline measurement of kidney function that can be used to monitor 
For side-effects of certain antihypertensive drugs on kidney function. 
Additionally, testing of urine samples for protein is used as a secondary indicator 
of kidney disease. Glucose testing is done to determine if diabetes mellitus is 
present. Electrocardiogram (EKG/ECG) testing is done to check for evidence of 
the heart being under strain from high blood pressure. It may also show if there is 
thickening of the heart muscle (left ventricular hypertrophy) or has experienced a 
prior minor heart distubance such as a silent heart attack. A chest X-ray may be 
performed to look for signs of heart enlargement or damage to heart tissue. 
Prevention 
The degree to which hypertension can be prevented depends on a number 
of features including current blood pressure level, sodium/potassium balance, 
detection and omission of environmental toxins, changes in end/target organs 
(retina, kidney, heart, among others), risk factors for cardiovascular diseases and 
the age at diagnosis of prehypertension or at risk for hypertension. A prolonged 
assessment in which repeated measurements of blood pressure are taken provides 
the most accurate assessment of blood pressure levels. Following this, lifestyle 
changes are recommended to lower blood pressure, before the initiation of 
prescription drug therapy. The process of managing prehypertension according the 
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guidelines of the British Hypertension Society suggest the following lifestyle 
changes: 
• Weight reduction and regular aerobic exercise (e.g., walking): Regular 
exercise improves blood flow and helps to reduce the resting heart rate and 
blood pressure.  
• Reducing dietary sugar. 
• Reducing sodium (salt) in the body by disuse of condiment sodium and the 
adoption of a high potassium diet which rids the renal system of excess 
sodium. Many people use potassium chloride salt substitute to reduce their 
salt intake. 
• Additional dietary changes beneficial to reducing blood pressure include 
the DASH diet (dietary approaches to stop hypertension) which is rich in 
fruits and vegetables and low-fat or fat-free dairy products. This diet has 
been shown to be effective based on research sponsored by the National 
Heart, Lung, and Blood Institute. In addition, an increase in dietary 
potassium, which offsets the effect of sodium has been shown to be highly 
effective in reducing blood pressure.  
• Discontinuing tobacco use and alcohol consumption has been shown to 
lower blood pressure. The exact mechanisms are not fully understood, but 
blood pressure (especially systolic) always transiently increases following 
alcohol or nicotine consumption. Abstaining from cigarette smoking 
reduces the risk of stroke and heart attack which are associated with 
hypertension.  
Limiting alcohol intake to less than 2 standard drinks per day can reduce 
systolic blood pressure by between 2-4mmHg.  
• Reducing stress, for example with relaxation therapy, such as meditation 
and other mindbody relaxation techniques, by reducing environmental 
stress such as high sound levels and over-illumination can also lower 
blood pressure. Jacobson's Progressive Muscle Relaxation and biofeedback 
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are also beneficial, such as device-guided paced breathing, although meta-
analysis suggests it is not effective unless combined with other relaxation 
techniques.  
Increasing omega 3 fatty acids can help lower hypertension. Fish oil is 
shown to lower blood pressure in hypertensive individuals. The fish oil may 
increase sodium and water excretion.  
Treatment18 
Lifestyle modifications 
The first line of treatment for hypertension is the same as the 
recommended preventative lifestyle changes such as the dietary changes, physical 
exercise, and weight loss, which have all been shown to significantly reduce blood 
pressure in people with hypertension. If hypertension is high enough to justify 
immediate use of medications, lifestyle changes are still recommended in 
conjunction with medication. Drug prescription should take into account the 
patient's absolute cardiovascular risk (including risk of myocardial infarction and 
stroke) as well as blood pressure readings, in order to gain a more accurate picture 
of the patient's cardiovascular profile. Different programs aimed to reduce 
psychological stress such as biofeedback, relaxation or meditation are advertised 
to reduce hypertension. However, in general claims of efficacy are not supported 
by scientific studies, which have been in general of low quality.  
Regarding dietary changes, a low sodium diet is beneficial; A Cochrane 
review published in 2008 concluded that a long term (more than 4 weeks) low 
sodium diet in Caucasians has a useful effect to reduce blood pressure, both in 
people with hypertension and in people with normal blood pressure. Also, the 
DASH diet (Dietary Approaches to Stop Hypertension) is a diet promoted by the 
National Heart, Lung, and Blood Institute (part of the NIH, a United States 
government organization) to control hypertension. A major feature of the plan is 
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limiting intake of sodium, and it also generally encourages the consumption of 
nuts, whole grains, fish, poultry, fruits and vegetables while lowering the 
consumption of red meats, sweets, and sugar. It is also "rich in potassium, 
magnesium, and calcium, as well as protein". 
Medications 
Several classes of medications, collectively referred to as antihypertensive 
drugs, are currently available for treating hypertension. Agents within a particular 
class generally share a similar pharmacologic mechanism of action, and in many 
cases have an affinity for similar cellular receptors. An exception to this rule is the 
diuretics, which are grouped together for the sake of simplicity but actually exert 
their effects by a number of different mechanisms. 
Reduction of the blood pressure by 5 mmHg can decrease the risk of 
stroke by 34%, of ischaemic heart disease by 21%, and reduce the likelihood of 
dementia, heart failure, and mortality from cardiovascular disease. The aim of 
treatment should be reduce blood pressure to <140/90 mmHg for most individuals, 
and lower for individuals with diabetes or kidney disease (some medical 
professionals recommend keeping levels below 120/80 mmHg). If the blood 
pressure goal is not met, a change in treatment should be made as therapeutic 
inertia is a clear impediment to blood pressure control. Comorbidity also plays a 
role in determining target blood pressure, with lower BP targets applying to 
patients with end-organ damage or proteinuria.  
Often multiple drugs are combined to achieve the goal blood pressure. 
Commonly used prescription drugs include:  
• ACE inhibitors (e.g., captopril) 
• Alpha blockers (e.g., prazosin) 
• Angiotensin II receptor antagonists (e.g., losartan) 
• Beta blockers (e.g., propranolol) 
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• Calcium channel blockers (e.g., verapamil) 
• Diuretics (e.g. hydrochlorothiazide) 
• Direct renin inhibitors (e.g., aliskiren) 
  Some examples of common combined prescription drug treatments include: 
• A fixed combination of an ACE inhibitor and a calcium channel blocker. 
One example of this is the combination of perindopril and amlodipine, the 
efficacy of which has been demonstrated in individuals with glucose 
intolerance or metabolic syndrome.  
• A fixed combination of a diuretic and an ARB. 
Combinations of an ACE inhibitor or angiotensin II–receptor antagonist, a 
diuretic and an NSAID (including selective COX-2 inhibitors and non-prescribed 
drugs such as ibuprofen) should be avoided whenever possible due to a high 
documented risk of acute renal failure. The combination is known colloquially as 
a "triple whammy" in the Australian health industry. 
 In the elderly Treating moderate to severe high blood pressure with 
prescription medications decreases death rates in those under 80 years of age 
however there is no decrease in those over 80 years old. Even though there was no 
decrease in total mortality, the results showed similarities between cardiovascular 
mortality and morbidity.   
  
LITERATURE REVIEW 
 
   33 
 
LITERATURE REVIEW 
Literature Review For Microspheres 
 
 
 Dr.lakshmanu prabu, shirwaikar.AR et al, (2007) Prepare   the sustained 
release Aceclofenac  microspheres by uing rosin as an encapsulating polymer. The 
release rate of drug from the microspheres could be properly controlled for about 
24h. Appropriate variation in the proportions of drug; polymer and stabilizer can 
lead to a product with the desired controlled release features. 
 
 
 Vinay mishara et al., (2008) to Prepare and Evaluate matrix microspheres 
system for simultaneous and sustained release of Candesartan cilexetil and 
captopril for the management of nephritic syndrome, Ethyl cellulose was used as a 
retardant polymer  decrease of side effect, increase of bioavailability and 
therapeutic action of both combination drugs. 
 
 KBR chowdary, Dana (2008) reported that the study is to evaluate ethylcellulose 
as a coat for controlled release microcapsules of diclofenac. Ethylcellulose coated 
microcapsules were prepared by an emulsion-solvent evaporation method 
employing different proportions of core and coat and the microcapsules were 
evaluated for size, drug content and microencapsulation efficiency. 
 
 Rajashree hirlekar et al., (2008) to develop bucoadhesive drug delivery system 
of Metoprolol tartarate using various polymer like sodium carboxy methyl 
cellulose and natural polymers like gum karaya, xanthum gum and locust bean 
gum. The formulation containing xanthum gum and locust bean gum in 2:1 ratio 
exhibited complete drug release in 45 minutes. 
 
Vadhana singh et al., (2009) Develop the hollow microspheres as a new dosage  
form of floating drug delivery system with prolonged stomach retention time.        
Hollow microspheres containing ranitidine hydrochloride were prepared by 
solvent evaporation method using Eudragit RLPO dissolved in a mixture 
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of dichloromethane and ethanol. Hollow microspheres could prolong drug release 
time (approximately 24 hrs) and float over stimulate gastric fluid for more than 
12hrs 
 
Kem et al., (2009) to Production of uniform microspheres and double-wall  
microspheres capable of efficiently encapsulating model drugs. Of primary 
importance was the ability of monodisperse microsphere formulations. 
Monodisperse PPF microspheres and core-shell microparticles offer advantages 
in reproducibility, control, and consistency that may provide valuable assistance in 
designing advanced drug delivery systems. to achieve precise control of the 
particle size and reproducibly fabricate nanocapsules the technology  
  
 Om praksh et al., (2009) Evaluate rosin polymer , Rosin application agent, 
microencapsulating,agent. It had been found anti-inflammatory and antitumor 
activity. Its semisolid preparation such as skin cream shows good homogeneity 
and spreadibility. It has prominent property for the sustained release drug system 
with most of the drug and dosage form. 
 
Alaghusundram., et al., (2009) reported microspheres  not only for prolonged 
release, but also for targeting of anticancer drugs to the Tumour. In future by 
combining various other strategies, Microspheres will find the central place in 
novel drug delivery, particularly in diseased cell sorting, diagnostics, gene & 
genetic materials, safe, targeted and effective in-vivo. 
 
 
Amal H. et al., (2009) To formulate and evaluate captopril Sustained release 
microparticles.using acetate propionate and employing the solvent evaporation 
technique .it decreases the side effects.microparticles containing different dug and 
polymer ratio. 
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 Shashank tiwari. et al., (2010) To formulate micoencapsulation by solvent 
evaporation method (study of effect process variables) the properties of poly 
(lacticacid) (poly lactic co glycolic acid) the effect of this microencapsulation is 
successful .and to get a desire release rate and highest drug loading. 
 
 
 Anand,Chirag. et al., (2010) formulation and evaluation of floating  
micropsheres of captopril for prolong gastric residence time. Floating  
microspheres was formulated using biocompatible polymers like Eudragit S100 
and Ethyl cellulose in different proportions by solvent evaporation technique. The 
prepared microspheres were evaluated for percentage yield, micromeritic 
properties, particle size, morphology, drug entrapment, buoyancy studies, In vitro 
drug release studies. Practical yield of the microspheres. 
 
Umamaheshwari. et al., (2010) was the fabricate modified release tablets of 
Floating microsphere bearing acetohydroxamic acid for the treatment of  
H.pylori.using different portion of drug and polymer. 
 
Durgacharan .et al.,(2011) Formulation and evaluation of Controlled Release 
Microspheres of Isosorbide dinitrate . Microspheres of Isosorbide dinitrate were 
prepared using the non-aqueous emulsification solvent evaporation method. The 
impacts of different factors such as stirring rate, concentration of acrycoat S 100 
as matrix polymer on the characteristics of the microspheres were investigated.  
 
 Durgacharan,Mangesh R. et al., (2011) Formulation and evaluation of 
Controlled Release Microspheres of Isosorbide dinitrate Microspheres of 
Isosorbide dinitrate were prepared using the non-aqueous emulsification solvent 
evaporation method. The impacts of different factors such as stirring rate, 
concentration of acrycoat S 100 as matrix polymer on the characteristics of the 
microspheres were investigated and study.  
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Sudhamani . et al., (2011) Preparation and evaluation of ethyl cellulose 
micropsheres of ibuprofen for sustained drug delivery These ethylcellulose 
microspheres were prepared by the solvent evaporation method. The prepared 
microspheres were subjected to various evaluation and invitro release studies. 
Highest percentage of loading was obtained by increasing the amount of ibuprofen 
with respect to polymer. The particle sizes of the prepared microspheres were 
determined  
 
Kumar,Ankit .et al.,(2011)  Evaluate  Microencapsulation This approach 
facilitates accurate delivery of small quantities of potent drugs, reduced drug 
concentrations at sites other than the target organ or tissue and protection of labile 
compounds before and after administration and prior to appearance at the site of 
action. Microencapsulation system offers potential advantages over conventional 
drug delivery systems. Microspheres and microparticales are a unique carrier 
system for various pharmaceuticals dosage form. 
 
Hermen nack.et al., (1969) Microencapsulation Techniques, application and 
problems. Evaluation of microcapsules of acetyl salicylic acid prepared with 
cellulose acetate phthalate, ethyl cellulose or their mixtures by an emulsion non-
solvent addition technique. 
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3. AIM AND OBJECTIVE  
AIM  
The aim of the present study was to prepare sustained release captopril 
microspheres using biodegradable polymer. 
OBJECTIVE 
¾ Developing sustained release microspheres matrix system containing 
captopril using rosin as the natural polymer  
¾ The drug release will be sustained for a longer period of time 
¾ The dose will be reduced that improve the patient compliance.  
 
Microencapsulation is the process in which small droplets or particles of 
liquid or solid material are surrounded or coated by a continuous film of 
polymeric materials. The controlled drug delivery system has used to reduce the 
problems associated with conventional therapy and to improve the therapeutic 
efficacy of a given drug. The maximum therapeutic efficacy can be achieved by 
delivering of the active agent in the optimal rate to the target tissue, then causing 
little toxicity and minimum side effects. To deliver a therapeutic substance to the 
target site in a sustained controlled release fashion, various approaches are used. 
One is by using microspheres as carriers for drugs. Microspheres are considered 
as free flowing powders consisting of polymers which are biodegradable in nature 
and they have the particle size below 200µm. 
 
Microencapsulation process helps for controlling the release characteristics 
of different coated materials. Microencapsulation the small coated particles are 
used to make to a wide variety of dosage forms and have not been feasible. Novel 
drug delivery systems which were initiate with the course of optimizing the 
bioavailability by the modification of the bioavailability of the drug concentration 
in blood.  With the sustained and controlled release products, drug therapy can be 
improved that is the common goal achieved over with their non sustained and 
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controlled release with the same drug. Microencapsulated products (micro 
particles) are the small entities that have an active agent know as the core material 
surrounded by a shell known as the coating material or embedded into a matrix 
structure. Most microparticle shells are of organic polymers, but waxes and lipids 
are also used. Generally the size of the microencapsulated products is considered 
as larger than micrometer and up to 1000 micrometers in diameter. Commercially 
available microparticles contained 10-90% w/w core. The more recent result of 
pharmaceutical research is that the absorption rate of a drug can be controlled by 
controlling its rate of release from the dosage form .The controlled released 
dosage forms are so designed and formulated as having the sustained action, 
sustained release, prolonged action, delayed action and timed release medication. 
This has been done by developing the new drug entities, discovering of new 
polymeric materials that are suitable for prolonging the drug release, safety, 
improvement in therapeutic efficacy.  
 
 The main reason for microencapsulation is for sustained or prolonged 
release of the drug. Microencapsulation technique also helpful to prevent the 
incompatibility between drugs.Microencapsulation has also been employed to 
change the site of absorption. This application has been useful for those drugs 
which have the toxicity at lower pH.  
  
Captopril, an antihypertensive agent, has been widely used for the 
treatment of hypertension and congestive heart failure. It has been reported, 
however, that the duration of antihypertensive action after a single oral dose of 
captopril is only 6–8 h, so clinical use requires a daily dose of 37.5–75 mg to be 
taken three times. It is most stable at pH 1.2 and as the pH increases; it becomes 
unstable and undergoes a degradation reaction. Thus a sustained and controlled 
release dosage form of captopril is desirable. Hence an attempt has been made to 
design a microsphere system of captopril using rosin polymer for prolonged 
improve the Release profile of drug. 
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4. PLAN OF WORK  
 
¾ Collection of drug and Polymer 
¾ Preformulation study: 
 
9 Description 
9 Solubility 
9 Melting  point 
9 Identification of the drug 
                 UV absorption maxima 
                FT-IR Studies 
9 Compatibility studies 
     
¾ Formulation of Microspheres 
¾ Evaluation parameters 
 
 Particle size analysis 
 Shape and Surface morphology by Scanning Electron 
Microscopy  
 Percentage Yield 
 Drug Content Analysis  
 Percentage Drug Entrapment 
 In- vitro dissolution study   
 
¾ Stability studies 
¾ Release kinetics 
¾ Results and discussion 
¾ Conclusion  
  
DRUG AND EXCIPIENTS PROFILE   
 
   40 
 
5.DRUG PROFILE 
 
 5.1CAPTOPRIL15,16,17 
 
Category  
    It inhibits the activity of anginotensin converting enzyme 
 
Molecular formula 
                                  C9H15NO3S 
 
Molecular weight 
                                   217.285 
 
Chemical name 
        (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid 
 
 Description 
Nature 
  White to off white crystalline powder 
 
Solubility 
    Soluble in water, chloroform and alcohol 
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Physical data 
Melting point 
1600C 
Pharmacokinetic data 
Protein binding 25-30% bound to plasma proteins, primarily albumin 
 
Volume of distribution Not Available 
Bioavailability 
70% 
Metabolism 
Hepatic 
Half Life 
2hours 
Excretion 
 
Renal 
 
 Mechanism of action 
 
There are two isoforms of ACE: the somatic isoform, which exists as a 
glycoprotein comprised of a single polypeptide chain of 1277; and the testicular 
isoform, which has a lower molecular mass and is thought to play a role in sperm 
maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two 
functionally active domains, N and C, which arise from tandem gene duplication. 
Although the two domains have high sequence similarity, they play distinct 
physiological roles. The C-domain is predominantly involved in blood pressure 
regulation while the N-domain plays a role in hematopoietic stem cell 
differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of 
both domains, but have much greater affinity for and inhibitory activity against 
the C-domain. Captopril, one of the few ACE inhibitors that is not a prodrug, 
competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of 
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ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by 
inhibiting the pressor effects of ATII as described in the Pharmacology section 
above. Captopril also causes an increase in plasma renin activity likely due to a 
loss of feedback inhibition mediated by ATII on the release of renin and/or 
stimulation of reflex mechanisms via baroreceptors. Captopril’s affinity for ACE 
is approximately 30,000 times greater than that of ATI. 
 Indications 
For the treatment of essential or renovascular hypertension (usually 
administered with other drugs, particularly thiazide diuretics). May be used to 
treat congestive heart failure in combination with other drugs (e.g. cardiac 
glycosides, diuretics, ß-adrenergic blockers). May improve survival in patients 
with left ventricular dysfunction following myocardial infarction. May be used to 
treat nephropathy, including diabetic nephropathy. 
   Side effects 
• feeling light-headed, fainting; 
• urinating more or less than usual, or not at all; 
• fever, chills, body aches, flu symptoms; 
• pale skin, feeling light-headed or short of breath, rapid heart rate, trouble 
concentrating; 
• Easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple 
or red pinpoint spots under your skin; 
• fast, pounding, or uneven heartbeats; 
• chest pain; or 
• swelling, rapid weight gain. 
Less serious captopril side effects may include: 
• cough; 
• loss of taste sensation, loss of appetite; 
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• dizziness, drowsiness, headache; 
• sleep problems (insomnia); 
• dry mouth, sores inside your mouth or on your lips; 
• nausea, diarrhea, constipation; or 
• mild skin itching or rash. 
 Dosage 
Usual Adult Captopril Dose for Hypertension: 
Initial dose: 25 mg orally 2 to 3 times a day one hour before meals. 
Maintenance dose: 25 to 150 mg orally 2 to 3 times a day one hour before meals. 
Usual Adult Captopril Dose for Congestive Heart Failure: 
Initial dose: 25 mg orally 3 times a day (6.25 to 12.5 mg orally 3 times a 
day if volume . 
Maintenance dose: After a dose of 50 mg three times a day is reached, 
further increases in dosage should be delayed, where possible, for at least 2 weeks 
to determine if a satisfactory response occurs. Most patients studied have had a 
satisfactory clinical improvement at 50 to 100 mg three times a day. 
Captopril should generally be used in conjunction with a diuretic and digitalis. 
Usual Adult Captopril Dose for Left Ventricular Dysfunction: 
Initial dose:  
6.25 mg orally for one dose, then 12.5 mg orally 3 times a day. 
Increasing dose: The dose is increased to 25 mg orally 3 times a day during the 
next several, days. 
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Maintenance dose:  
The dose is increased to a target dose of 50 mg orally 3 times a day  
Therapy may be initiated as early as three days following a myocardial infarction. 
Captopril may be used in patients treated with other post-myocardial infarction 
therapies, e.g., thrombolytics, aspirin, beta blockers. 
Usual Adult Captopril Dose for Diabetic Nephropathy: 
The recommended dose for long-term use is 25 mg orally 3 times a day. 
Usual Adult Captopril Dose for Hypertensive Emergency: 
When prompt titration of blood pressure is indicated, continue diuretic 
therapy and halt current medication therapy and initiate 25 mg two or three times 
daily under close supervision. Increase the dose every 24 hours or less until a 
satisfactory response is obtained or the maximum dose is reached. 
Usual Adult Captopril Dose for Cystinuria: 
Initial dose:  
25 mg orally 2 to 3 times a day one hour before meals. Initial doses may 
be titrated as tolerated approximately every 1 to 2 weeks to reduce the degree of 
cystinuria. 
 
         Limited data have shown significant reductions in the urinary excretion of 
cystine after daily doses of captopril of 150 mg. 
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Dosage forms 
Form   Route   Strength 
Tablet   Oral   100 mg 
Tablet   Oral   12.5 mg 
Tablet   Oral   25 mg 
Tablet   Oral   50 mg 
 
5.2 EXCIPIENT PROFILE,21.32.44 
Polyvinyl  Alcohol 
 
 Nonproprietary Names 
 
      PhEur :  Poly(vinylis acetas) 
      USP :  Polyvinyl alcohol 
 
Synonyms 
Airvol; Alcotex; Elvanol; Gelvatol; Gohsenol; Lemol; Mowiol; Polyvinol; 
PVA; vinyl alcohol ,polymer. 
 
Chemical Name and CAS Registry Number 
 
Ethenol, homopolymer [9002-89-5] 
 
Empirical Formula and Molecular Weight 
 
 (C2H4O)n 20 000–200 000 
 
   Polyvinyl alcohol is a water-soluble synthetic polymer represented by the 
formula (C2H4O)n. The value of n for commercially available materials lies 
between 500 and  5000, equivalent to a molecular weight range of approximately 
20 000–200 000. 
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Grade Molecular weight 
High viscosity  - 200 000 
Medium viscosity  - 130 000 
Low viscosity   - 20 000 
 
Structural Formula 
 
Functional Category 
 
   Coating agent; lubricant; stabilizing agent; viscosity-increasing agent. 
  Pharmaceutical Excipients  
 
Applications in Pharmaceutical Formulation or Technology 
Polyvinyl alcohol is used primarily in topical pharmaceutical and 
ophthalmic formulations. 
 
Use Concentration (%) 
Emulsions 0.5 
Ophthalmic formulations 0.25–3.00 
 
Topical lotions 2.5 .1–3 It is used as a stabilizing agent for emulsions 
(0.25–3.0% w/v). Polyvinyl alcohol is also used as a viscosity-increasing agent for 
viscous formulations such as ophthalmic products. It is used in artificial tears and 
contact lens solutions for lubrication purposes, in sustained release formulations 
for oral administration,4 and in transdermal patches.5 Polyvinyl alcohol may be 
made into microspheres when mixed with a glutaraldehyde solution. 
 
Description 
    Polyvinyl alcohol occurs as an odorless, white to cream-colored granular 
powder. 
 
Pharmacopeial Specifications 
 
    Pharmacopeial specifications for polyvinyl alcohol. 
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  Test PhEur 2005 USP 28 
   Viscosity     =  + 
   pH 4.5    = 6.5 5.0–8.0 
   Loss on drying    = _5.0% =_5.0% 
   Residue on ignition    = í1.0% =í2.0% 
   Water-soluble substances   = Ê0.1% 
   Degree of hydrolysis   = H0.1% 
   Organic volatile impurities   =  + 
   Pharmaceutical Excipients   = 2215  
 
  Test PhEur 2005 USP 28 
      
Assay - 85.0–115.0% 
 
Typical Properties 
 
Melting point: 
 
 228°C for fully hydrolyzed grades; 
 180–190°C for partially hydrolyzed grades. 
 
Refractive index: 
n25 
D = 1.49–1.53 
 
Solubility: 
Soluble in water; slightly soluble in ethanol (95%); insoluble in organic 
solvents. Dissolution requires dispersion (wetting) of the solid in water at room 
temperature followed by heating the mixture to about 90°C for approximately 5 
minutes. Mixing should be continued while the heated solution is cooled to room 
temperature. 
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Specific gravity: 
 
 1.19–1.31 for solid at 25°C; 
 1.02 for 10% w/v aqueous solution at 25°C. 
 
Specific heat: 
1.67 J/g (0.4 cal/g) 
 
Viscosity (dynamic): 
Viscosity of commercial grades of polyvinyl alcohol. 
 
Grade Dynamic viscosity of 4%w/v aqueous solution at 20°C (mPa s) 
Pharmaceutical Excipients 2215 
 
Grade Dynamic viscosity of 4%w/v aqueous solution at 20°C (mPa s) 
 
High viscosity 40.0  = 65.0 
Medium viscosity 21.0 = 33.0 
Low viscosity 4.0  = 7.0  
 
11. Stability and Storage Conditions 
 
 Polyvinyl alcohol is stable when stored in a tightly sealed container in a 
cool, dry place. 
 Aqueous solutions are stable in corrosion-resistant sealed containers. 
Preservatives may be added to the solution if extended storage is required. 
Polyvinyl alcohol undergoes slow degradation at 100°C and rapid 
degradation at 200°C; it is stable on exposure to light. 
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12. Incompatibilities 
 
Polyvinyl alcohol undergoes reactions typical of a compound with 
secondary hydroxyl groups, such as esterification. It decomposes in strong acids, 
and softens or dissolves in  weak acids and alkalis. It is incompatible at high 
concentration with inorganic salts, especially sulfates and phosphates; 
precipitation of polyvinyl alcohol 5% w/v can be caused by phosphates. Gelling of 
polyvinyl alcohol solution may occur if borax is present. 
 
13. Method of Manufacture 
  
Polyvinyl alcohol is produced through the hydrolysis of polyvinyl acetate. 
The repeating unit of vinyl alcohol is not used as the starting material because it 
cannot be obtained in the quantities and purity required for polymerization 
purposes. The hydrolysis proceeds rapidly in methanol, ethanol, or a mixture of 
alcohol and methyl acetate, using alkalis or mineral acids as catalysts. 
 
14. Safety 
 
Polyvinyl alcohol is generally considered a nontoxic material. It is 
nonirritant to the skin and eyes at concentrations up to 10%; concentrations up to 
7% are used in cosmetics. 
 
Studies in rats have shown that polyvinyl alcohol 5% w/v aqueous solution 
injected subcutaneously can cause anemia and infiltrate various organs and 
tissues. 
 
 LD50 (mouse, oral) :  14.7 g/kg 
  LD50 (rat, oral) :  >20 g/kg 
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15. Handling Precautions 
 
  Observe normal precautions appropriate to the circumstances and quantity 
of material  handled. Eye protection and gloves are recommended. Polyvinyl 
alcohol dust may be an irritant on inhalation. Handle in a well-ventilated 
environment. Pharmaceutical    Excipients  
 
16. Regulatory Status 
 
Included in the FDA Inactive Ingredients Guide (ophthalmic preparations 
and oral tablets). Included in nonparenteral medicines licensed in the UK. 
Included in the Canadian List of Acceptable Non-medicinal Ingredients. 
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6.MATERIALS AND METHODS  
LIST OF MATERIALS 
Table- 2. List of Materials Used 
S.NO Materials Manufacturer 
1. Captopril Gift sample obtained from Madras pharmaceuticals, Chennai. 
2. Rosin Gift sample obtained from madras pharmaceuticals, Chennai. 
3. Dicholoromethane Nice Chemicals Private Limited, Chennai.  
4. Sodium chloride Nice Chemicals Private Limited, Chennai.  
5. Methanol Nice Chemicals Private Limited, Chennai.  
6. Poly vinyl alcohol Nice Chemicals Private Limited, Chennai. 
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6.2  LIST OF EQUIPMENTS 
 
Table-3  List of Equipments Used 
S.No Equipments Manufacturer Use 
1 
UV-Visible double beam 
spectrophotometer 
Shimadzu UV 1700, 
Japan.  
To measure the 
absorbance of the sample 
2 Electronic Balance Sortorius Single Pan For weighing purpose 
3 
Programmable Dissolution 
test apaarataus 
ElectroLab 
(Tablet Dissolution 
tester USP 24) 
For in-vitro dissolution 
studies 
4. pH meter Elico L 1120 
To measure the pH of the 
solution 
5. 
Environmental stability 
testing chamber 
Heco Environment 
Chamber 
For stability studies 
6. FT-IR Perkin Elmer  
For compatibility 
analysis 
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7.PREFORMULATION  
Preformulation testing is the first step in the rational development of 
dosage forms of a drug substance. It can be defined as an investigation of physical 
and chemical properties of a drug substance alone and when combined with 
excipients. The overall objective of pre-formulation testing is to generate 
information useful to the formulator in developing stable and bio available dosage 
forms that can be man produced. 
 
The following preformulation studies are carried out: 
 
¾ Description 
¾ Solubility 
¾ Melting point 
¾ Finding the absorption maxima 
¾ Standard curve 
¾ Infra red spectroscopy studies (compatibility studies)   
Description  
            About 1g of sample is taken in a dry Petidish and the sample is observed 
for compliance against the specification. 
 
Melting Point  
                Capillary tube, which is sealed at one end is charged with sufficient 
amount of dry powder to form a column in the bottom of the tube 2.5mm to 
3.5mm when packed down as closely as possible by moderate tapping on a solid 
surface. The apparatus is operated according to the standard operating procedure. 
The block is heated until the temperature is about 30°c below the expected 
melting point. 
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               The capillary tube is inserted into the heating block, and the heating is 
continued at a rate of temperature increased of about 1°c to 2°c per minute until 
melting is complete. The temperature at which the detector signal first leaves its 
initial value is defined as the beginning of melting, and the temperature at which 
the detector signal reaches its final value is defined as the end of melting, or the 
melting point. The two temperature fall within the limits of melting range.  
 
Solubility Studies  
                   
The spontaneous interaction of two or more substance to form a 
homogeneous molecular dispersion is called as solubility. A semi quantitative 
determination of the solubility was made by adding solvent in small incremental 
amount to a test tube containing fixed quantity of solute or vice versa. After each 
addition, the system vigorously shaken and examined visually for any undisclosed 
solute particles. The solubility was expressed in turns of ratio of solute and 
solvent. 
 
The approximate solubility’s of substances are indicated by the descriptive 
terms in the accompanying table. The results are shown in table. 
 
                                 Table 4 -   Solubility profile I.P.1996  
 
Descriptive term Parts of solvent required for 1 part of solute. 
Very soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 10 to 30 
Sparingly Soluble From 30 to 100 
Slightly Soluble From 100 to 1000 
Very slightly soluble From 1000 to 10, 000 
Practically insoluble of Insoluble Greater than or equal to 10,000 
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Identification of the drug: 
Finding the absorption maxima (λ max) 
 
The absorption maxima were found for drug identification. Ultraviolet 
Visible spectrophotometry has been used to obtain specific information on the 
chromophoric part of the molecules. Organic molecules in solutions when 
exposed to light in the visible/Ultraviolet region of the spectrum absorb light of 
particular wavelength depending on the type of electronic transition associated 
with the absorption. 
 
        The various batches of the microspheres were subjected for drug content 
analysis. Accurately weighed microsphere samples were mechanically powdered. 
The powdered microspheres were dissolved in adequate quantity of phosphate 
buffer PH 7.2 then filter. The UV absorbance of the filtrate was measured using a 
UV spectrometer at 203nm. 
 
Fourier transform infrared (FTIR) spectral analysis 
 
FT-IR is used to identify the functional groups in the molecule. The drug 
is mixed with KBr and pellet is formed. Each KBr disk was scanned at 4 mm/s at 
a resolution of 2 cm over a wave number region of 400 to 4,500 cm−1. The 
characteristic peaks were recorded. The results are shown in the following figure. 
and table. 
 
Drug-Excipient Compatibility studies by FT-IR 
 
Fourier infrared spectroscopy (FT-IR) analysis was performed for the pure 
drug and physical admixtures (Polymers, excipients) individually and then the 
drug and physical admixtures are mixed together and FT-IR is taken to find out 
that there is no interaction between drug, polymers and the excipients.The results 
are shown in the following figure.and table. 
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Standard Curve 
 
The drug solutions (10,20,30,40 and 50µg/ml) were taken in a standard 
cuvette and scanned in the range of 200-400nm by using UV-Spectrophotometer. 
The absorbance of each sample was measured at 202.4nm. The standard curve is 
plotted against absorbance and concentration of the sample. Similarly, the 
procedure can be repeated for phosphate buffer pH 7.2. The values are given in 
the following Table  and figure. 
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8.FORMULATION OF MICROSPHERES 20,27,30,40 
Captopril micropsheres prepare by using rosin as a polymer by solvent 
evaporation method. 
                                  Fig -6 Emulsion solvent techniques 
EMULSION SOLVENT EVAPORATION TECHNIQUE
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FORMULATION OF MICROSPHERES21,30,34 
¾ Microspheres were prepared by the solvent evaporation method using 500 
mg of captopril and with different proportion of polymer  were dissolved 
in the dichloromethane 5ml This flowable mass was introduced in to 50ml 
of aqueous saline phase (0.9%Nacl)containing 0.04%PVA(20)mg and 
10% methanol (5ml) . 
¾ The system is stirred using propeller at 300 rpm room temperature for 2-3 
hours the drug loaded floating microsphere formed filtered Whatman 
filtered paper 
 
                               Process Flow Chart of micropsheres 
    Drug (Captopril) + Polymer (rosin)  
                      
                                               Dissolve in dichloromethane  
                                                                Injected  
 
     Nacl + PVA+ Methanol+ water containing solution  
 
        Stirred at 500 rpm for 2-3 hours 
 
         Formation of microspheres 
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   8.2 FORMULATION OF MICROSPHERES  
Fig -7  microspheres 
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  8.3 FORMULATION OF MICROSPHERES 22,32 
                    Table -5  Formula  for  Captopril  Microspheres 
Ingredients 
              Formulation Ratios  
F1 F2 F3 F4 F5 
Captopril 50 mg 50 mg 50 mg 50mg 50mg 
Rosin 150 mg 200mg 250mg 300mg 350mg 
Dichloromethane 5ml 5ml  5ml   5ml  5ml  
Sodium chloride 450mg 450mg 450mg 450mg  450mg  
Poly vinyl alcohol 20mg 20mg 20mg  20mg  20mg  
Methanol 5ml 5ml  5ml  5ml  5ml  
Water 50ml 50ml  50ml  50ml  50ml  
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CHARACTERIZATION OF MICROSPHERES24,28 
The prepared captopril micropsheres were characterized for various 
characters such as particle size, surface morphology, entrapment efficiency, drug 
content, in-vitro drug release study. 
 
Determination of particle size distribution by Particle size analyzer 
 
The selected best metoclopramide microbeads formulation (F6) was subjected 
to laser particle counting method. Here the sample was injected into the sample 
delivery and controlling chamber. Then, suitable solvent was pumped through the 
chamber. Now a beam of laser light was allowed to fall on the sample cell. After required 
number of runs, they were directed towards the detector. From this the particle size range 
and the average mean particle size of the formulation can be studied. 
 
The average particle size of F--------------- formulation can be determined 
using particle size analyzer. The results are shown in the figure.------------------- 
 
Scanning Electron Microscopy:  
 
The purpose of the Scanning Electron Microscopy study was to obtain a 
topographical characterization of micropsheres. The micropsheres were mounted 
on brass stubs using double-sided adhesive tape. Scanning electron microscopy 
photographs were taken with a scanning electron microscope (JSM-5610LV, Joel 
Ltd, Tokyo, Japan) at the required magnification at room temperature. The 
working distance of 39 mm was maintained, and the acceleration voltage used was 
15 kV, with the secondary electron image as a detector.  
 
Yield of Microspheres 
 
The prepared Microspheres were collected and weighed. The actual weight 
of obtained Microspheres divided by the total amount of all non-volatile material 
that was used for the preparation of the Microspheres multiplied by 100 gives the 
% yield of Microspheres . 
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This was calculated by the use of following formula. 
 % yield= (Actual weight of the product / Total weight of excipients and drug) × 
100 
 
Determination of Drug Content and Entrapment Efficiency  
 
100 mg of accurately weight microspheres were suspended in a phosphate 
buffer pH 7.2 upto 24 hours. Next day, the sample was shaken using mechanical 
shaker for few hours. Then it was filtered and from the filtrate, few ml of aliquot 
was taken and made the suitable dilutions and analyzed for the drug content at 
202.4 nm by spectrophotometry. The % of Entrapment Efficiency was calculated. 
Taking into the consideration the dilution factor and the amount of micro beads 
takes, the amount of drug entrapment per unit weight of micro beads were 
calculated.The drug entrapment efficiency was calculated using for the formula 
 
                                                            Practical drug content 
Percentage entrapment efficiency = ------------------------------ × 100 
                                                            Theoritical drug content 
Dissolution studies 
The dissolution studies were carried out using basket type apparatus at 50 
rpm and 37±0.5°C.  20 mg of drug were filled into colorless hard gelatin capsules 
and placed in basket separately. The dissolution medium was phosphate buffer pH 
7.2 as simulated intestinal fluid (SIF) for 12 hrs. 5 ml samples were withdrawn at 
specified time intervals and same volume was replaced immediately with an equal 
volume of fresh medium.  Samples were analyzed at 202.4 nm (Shimadzu 1700). 
The In-vitro drug release studies results were mentioned in the following table. 
 
Dissolution Study 
 
Apparatus   :  USP (basket) 
Speed    :  50 rpm 
Time    :  1,2,3,4,5,6,7,8,9,10,11,12th hour 
Temperature   :  37°C ± 0.5°C 
λmax    :  308.2 nm 
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Kinetics of drug Release,34.39  
 
Several theories and kinetic models describe the dissolution of drug from 
immediate release and modified release dosage forms. There are several models to 
represent the drug dissolution profiles where f (t) is a function of time related to 
the amount of drug dissolved from the pharmaceutical dosage form. 
                The quantitative interpretation of the values obtained in the dissolution 
assay is facilitated by the usage of a generic equation that mathematically 
translates the dissolution curve function of some parameters related with the 
pharmaceutical dosage forms. Drug dissolution from solid dosage forms has been 
described by kinetic models in which the dissolved amount of drug (Q) is a 
function of the test time‘t’ or Q(t). Some analytical definitions of the Q(t) function 
are commonly used, such as zero order, first order, Higuchi, Korsmeyer-Peppas, 
Hixson-Crowell models, Weibull models. These models are used to characterize 
drug dissolution/release profiles. 
 
(i) Zero Order Kinetics 
This model represents an ideal release profile in order to achieve the 
pharmacological prolonged action. Zero order release constitutes drug release 
from the dosage form that is independent of the amount of drug in the delivery 
system (that is, a constant release rate). The following equation is used to express 
the model: 
 
Qt = Qo + Kot 
 
Where, Qt is the amount of drug dissolved in time t 
Qo is the initial amount of drug in the solution 
                                    Ko is the zero order release constant 
 
For practical purposes the equation is rearranged: 
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Percent drug released = Kt 
 
This is applicable to dosage forms like transdermal systems, coated dosage 
forms, osmotic systems as well as matrix tablets with low soluble drugs. 
 
(ii) First Order Kinetics 
 
First order release constitutes drug release in a way that is proportional to 
the amount of drug remaining in its interior; in such a way that amount of drug 
released by unit time diminish. The following equation is used to express the 
model: 
 
log Qt = log Qo + Kt/2.303 
 
Where, Qt is the amount of drug dissolved in time t 
 Qo is the initial amount of drug in the solution 
                          K is the first order release constant 
 
For practical purposes the equation is rearranged: 
 
Log % of drug unreleased = Kt/2.303 
 
This model is applicable to dosage forms such as those containing water-
soluble drugs in porous matrices. 
 
(iii) Higuchi Model 25 
 
Higuchi describes drug release as a diffusion process based in Fick’s 
law,square root dependent. The following equation is used to express the model: 
 
Qt = Kht1/2 
 
Where,  
Qt is the amount of drug dissolved in time t 
Kh is the first order release constant 
For practical purposes the equation is rearranged: 
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Percent drug released = Kt1/2 
 
This model is applicable to systems with drug dispersed in uniform 
swellable polymer matrix as in case of matrix tablets with water soluble drug 
 
(iv) Peppas-Korsmeyer Model32 
 
This model is widely used when the release mechanism is not well known 
or when more than one type of release phenomenon could be involved 
 
The following equation is used to express the model 
 
           Qt/Q∞ = Ktn 
Where,  
 
Qt is the amount of drug dissolved in time t 
                      Q∞ is the amount of drug dissolved in infinite time 
n is the release exponent indicative of drug release mechanism 
K is the kinetic constant 
 
For practical purposes the equation is rearranged: 
 
Log percent drug released = log k +n log t 
 
Peppas used n value in order to characterize different release mechanism 
concluding for values of n = 0.5 for Fickian diffusion and values of n, between 0.5 
to 1.0 for anomalous transport (corresponds to diffusion, erosion and swelling 
mechanism or mixed order kinetics) and higher values of n, n=1 or n>1 for case-II 
transport (corresponds to erosion and relaxation of swollen polymer layer). 
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Stability Study   
Accelerated Stability Studies38  
Stability 
 
Stability is officially defined as the time lapse during which the drug 
product retains the same property and characteristics that it possessed at the time 
of manufacture. This process begins at early development phases. 
 
Definition 
Stability of a pharmaceutical preparation can be defined as “the capability 
of a particular formulation (dosage form or drug product) in a specific 
container/closure system to remain within its physical, chemical, microbiological, 
therapeutic and toxicological specifications throughout its shelf life.  
 
Instability in modern formulation is often undetectable only after 
considerable storage period under normal conditions. To assess the stability of a 
formulated product it is usual to expose it to high stress conditions to enhance 
deterioration and therefore the time required for testing is reduced. Common high 
stress factors are temperature and humidity. This will eliminate unsatisfactory 
formulation. 
 
Purpose of stability testing: 
 
¾ To study of drug decomposition kinetics 
¾ To develop stable dosage form 
¾ To establish the shelflife or expiration date for commercially available 
drug product. 
¾ To ensure the efficacy, safety and quality of active drug substance and 
dosage forms. 
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Table - 6 Stability Conditions Chart 
 
 
S.NO STUDY STORAGE  
CONDITION 
MINIMUM PERIOD 
1 Long term 25ºC ± 2ºC 
60% ± 5% RH 
12 months 
2 Intermediate  30ºC ± 2ºC 
65% ± 5% RH 
6 months 
3 Accelerated  40ºC ± 2ºC 
75% ± 5% RH 
6 months 
 
 
The stability studies of formulation F1 to F2 were carried out at 45° C ± 
2°C 75% ± 5% RH and leakage of the drug from the microspheres were analyzed 
in terms of percentage drug content. 
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9.RESULTS AND DISCUSSION  
PREFROMULATION: 
Description     -       White, Odourless powder. 
Melting point   -    106°C  
Solubility 
Table - 7    
Solubility Profile of Captopril 
 
S.NO SOLVENT SOLUBILITY 
1. Distilled water Very Soluble 
2. Alcohol freely soluble 
3. Ether Practically insoluble 
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Identification of Drug Sample - Absorption Maxima of 
 
 
Fig – 8 Captopril  in Phosphate buffer pH 7.2 
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Table - 8  
Standard curve in phosphate buffer pH 7.2 
S.No Concentration µg/ml Absorbance at 202.4 
nm 
1 10 0.2177 
2 20 0.4209 
3 30 0.5698 
4 40 0.8021 
5 50 0.9877 
6 60 1.2128 
 
 
Fig- 9 Standard curve 
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FTIR 
Fig – 10  IR Spectra of  Captopril 
  
 
Table – 9  
FTIR spectral Assignment of captopril 
 
S.No Wavenumber(cm-1) Assignment 
1 3943.39 N-H stretching 
2 2700.25 O-H stretching 
3 2452.86 C-H stretching 
4 2066.73 CH stretching 
5 1600.09 C=O stretching 
6 1399.60 C-O stretching 
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Fig – 11 IR spectra of Rosin 
 
 
Table - 10 IR Spectral Assignment of Rosin 
 
S.No Wave number (cm-1) Assignment 
1 3398.97 O-H stretching 
2 2967.72 C-H stretching 
3 1550.90 C=O stretching 
4 1383.84 C-O stretching 
5 1228.17 C-C stretching 
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Fig – 12 IR Spectra of Captopril and Rosin 
 
 
Table -11 IR Spectral Assignment of Captopril and rosin 
S.No Wave number (cm-1) Assignment 
1 2872.37 O-H stretching 
2 2554.90 C-H stretching aromatic 
3 2066.99 C-H stretching 
4 1598.81 C=O stretching 
5 1239.16 C-O stretching 
6 1112.13 C-C stretching 
7 963.66 C-H outplane bending 
 
FTIR RESULT: 
There are no extra peaks seen other than the normal peak in the spectra of 
the mixture of the drug and polymers and so there is no interaction with the drug 
and polymer and they are compatible with each other. 
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Particle size analysis 
 
 
Fig- 13 Particle size analysis 
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OPTICAL VIEW OF MICROSPHERE  
 
 
 
 
Fig- 14 
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SEM PHOTOMICROGRAPH OF CAPTOPRIL MICROPSHERES F5 
 
 
 
Fig – 15  SEM F 5 
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Percantage Yield 
 
Table – 12 
 
Percentage Yield 
 
S.NO Formulation code % Yielda 
1 F1 76.4 ± 2.72 
2 F2 74.4 ± 1.39 
3 F3 72.84 ± 0.84 
4 F4 78.33 ± 0.93 
5 F5 80.64 ± 1.12 
Values are mean ± SD, n=3. 
 
 
 
 
Fig -  16 Percentage yield 
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Determination of drug content 
 
Table – 13  
Drug Content 
 
S.NO Formulation code Drug contenta 
 
1 F1 87.64± 0.64 
2 F2 90.47± 0.46 
3 F3 89.84± 0.62 
4 F4 88.84± 0.74 
5 F5 92.63± 0.48 
Values are mean ± SD, n=3. 
 
 
 
 
Fig – 17 Percentage drug content 
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Table – 14  
Percentage entrapment efficacy 
 
S.NO Formulation % Entrapment 
Efficiency 
1 F1 81.74± 0.02 
2 F2 82.64± 0.53 
3 F3 81.73± 0.64 
4 F4 84.83± 0.74 
5 F5 89.94± 0.25 
Values are mean ± SD, n=3. 
 
 
 
 
Fig – 18 Percentage entrapment efficacy 
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Dissolution Study 
 
Table – 15 
Comparative Invitro drug release of Micropshere Formulations 
 
Time in 
hours 
Formulation code 
F1 F2 F3 F4 F5 
0 0 0 0 0 0 
1 34.04 30.68 28.92 22.48 21.46 
2 41.16 36.92 30.06 28.85 25.46 
3 49.52 42.08 40.56 37.95 35.93 
4 57.04 51.88 49.00 43.24 41.41 
5 63.64 59.72 57.84 51.84 49.42 
6 82.08 70.28 66.64 60.53 57.34 
7 98.27 81.64 74.04 68.84 64.94 
8  99.84 82.47 71.48 78.48 
9   97.12 73.95 82.98 
10    77.95 85.85 
11    80.04 87.95 
12    82.36 89.83 
 
 
 
  
RESULTS AND DISCUSSION  
 
   81 
 
 
 
Fig – 19 In-vitro release 
 
 
 
 
 
 
 
 
 
 
 
 
  
RESULTS AND DISCUSSION  
 
   82 
 
Table- 16 
Model fitting data for in-vitro release kinetic parameters of microspheres 
Formulation 
Code 
Zero 
order 
[r] 
First 
order 
[r] 
Higuchi 
[r] 
Hixson 
Crowell 
[r] 
Korsmeyer- 
Peppas [r] 
‘n ’- 
Values 
F1 0.923 0.953 0.991 0.804 0.651 0.520 
F2 0.971 0.884 0.991 0.815 0.704 0.6492 
F3 0.981 0.910 0.981 0.830 0.746 0.744 
F4 0.990 0.86 0.926 0.933 0.942 0.902 
F5 0.993 0.822 0.935 0.921 0.951 1.079 
 
n= Diffusion exponent related to mechanism of drug release, according to 
equation  Mt/M∞==Ktn, 
r = Correlation coefficient  
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Drug kinetics release 
Fig – 20 Drug kinetics release 
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10.7 Stability Study  
 
Table -17  
Stability Study for F5 formulation 
 
S.No Formulations Before 
storage 
Stored at 40°C ± 2°C and 
75% ± 5% RH 
 
1 
 
F5 
 
92.63±0.74
1st month 2nd month 3rd month 
91.63±0.74 90.63±0.74 89.63±0.74
 
The results showed that F5 formulation is stable for the period of 3 months 
without showing significant change in the drug content. 
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Discussion  
 
Captopril, an antihypertensive agent, with short half-life, low single dose 
administration and oral bioavailability is 65 %, was selected as a model drug to 
formulate a sustained release formulation with improved oral bioavailability. The 
drug captopril was identified by UV method. The maximum absorption was found 
at 202.4nm. Therefore further measurements were taken ta 202.4nm. 
 
The IR spectra of the drug and polymer combination were compared with 
the spectra of the pure drug and individual polymers in which no shifting of peaks 
was significantly found, indicating the stability of the drug during encapsulation 
process. The results were show in table 9 to 11. 
   
Microspheres were successfully prepared for the delivery of Captopril to 
enhance absorption and bioavailability. In concern to this approach, five 
formulations were prepared. In each formulation, the polymer concentration was 
varied. Rosin is a natural polymer. Incorporation of NaCl to the aqueous phase 
was necessary to prevent the dispersed phase from settling due to high density of 
dichloromethane, thereby making the dispersion and stabilization of the droplets 
by stirring difficult. Percentage yield of all formulation F1 to F5 were calculated 
and results are shown in Table 12. 
 
All formulations F1 to F5   micropheres were evaluated for particle size 
analysis (fig – 13)mean particle size range 40µm - 50µm. 
 
The microspheres of Captopril with rosin  were smooth, spherical and no 
aggregated (F5) results shown in fig – 15. 
 
As shown in table – 13, the F5 shows the maximum drug content  values 
of 92.63 %. Percentage Entrapment efficiency  were  shown in Table – 14, the F5 
– 89.94 %. As the polymer concentration was increased the drug entrapment 
efficiency % was increased due to increase in the viscosity of the solution. The 
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present investigation state that if the drugs are soluble in the solvent system, it 
results in high drug entrapment efficiency than that of dispersed in the solvent 
system. The elimination of the drugs from the prepared microspheres highly 
dependent on the concentration of the polymer used, as the amount of the polymer 
increased the entrapment efficiency of the microsphere increased because of the 
good matrix formation.  
   
Dissolution studies on all the five formulations of Captopril  microspheres 
were carried out using a USP  dissolution apparatus Type I. The In vitro drug 
release data for all formulations  shown in Table - 15 and Fig - 19. The cumulative 
percent drug release for F5 after 12 h was found to be 89.83 %. The cumulative 
drug release significantly decreased with increase in polymer concentration. The 
increased density of the polymer matrix at higher concentrations results in an 
increased diffusional pathlength. This may decrease the overall drug release from 
the polymer matrix. Furthermore, smaller microspheres are formed at a lower 
polymer concentration and have a larger surface area exposed to dissolution 
medium, giving rise to faster drug release. 
 
The data obtained from in vitro dissolution studies were fitted to zero-
order, first-order and Korsemeyer-Peppas equations. Fitting of the release rate 
data to the various models revealed that the formulation F1, F2, F4 and F5 
followed first order release kinetics. 
 
  In the case of the Fickian release mechanism, the rate of drug release is 
much less than that of polymer relaxation (erosion). So the drug release is chiefly 
dependent on the diffusion through the matrix. In the non-Fickian (anomalous) 
case, the rate of drug release is due to the combined effect of drug diffusion and 
polymer relaxation. Case II release generally refers to the polymer relaxation. The 
n values for formulations F1 to F5 ranged from 0.520 to 1.079, indicating that the 
release mechanism was non-Fickian or anomalous release (0.5 < n < 1). Based on 
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the n values, F1 to F5, drug release from microsphere were controlled by polymer 
relaxation (erosion) as well as diffusion. 
 
For the best formulation F5 were subjected to stability studies at 400 
C/75% RH up to 3 months. The microspheres  potency under accelerated stability 
conditions were within 90% to 110% of the label claim. Overall, results from the 
stability studies indicated that the spheres were chemically stable for more than 3 
months 
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10. CONCLUSION  
 
In this study sustained release Captopril Microspheres were prepared 
successfully using solvent evaporation method. It may be concluded that Captopril 
microspheres would be promising drug delivery system for oral administration of 
Captopril to sustained the drug release upto 12 h. 
 
The formulation was found to be efficient with good recovery yield, 
percentage drug entrapment.  FT-IR studies did not reveal any significant drug 
interactions. 
 
Captopril  microspheres are promising pharmaceutical dosage forms by 
providing sustained release drug delivery systems and avoiding the dose related 
side effects in the entire physiological region. 
 
Among the different formulations, microspheres containing F-5 was found 
to be it has higher release the drug of 89.83 ± 0.21 % at 12th hour. 
 
The diffusion of F5 formulation follows Zero order kinetics and fit into the 
Korsemeyer- peppas model and follows non-fickian,  
  
 Formulating Captopril  microspheres (F5) was successfully achieved. The 
drug release in a sustained manner upto 12 hours with less dose dumping. 
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